UMass team nabs $17M from NIAID to produce HIV vaccine


As HIV researchers around the globe work to advance vaccines against the devastating virus, the NIAID has awarded $17.3 million to the University of Massachusetts Medical School’s Dr. Shan Lu and colleagues to develop and manufacture a prime-boost candidate for a midstage trial.

As part of a program spanning 7 years, Lu’s team will work to create a manufacturing process for the experimental vaccine intended to produce doses for several hundred volunteers in a Phase II trial, according to the school’s release. If successful, the team could seek to leverage that progress for a Phase III trial ranging in the thousands of doses.

After two decades in HIV research, Lu said in a statement the manufacturing validation program is the “next stage” for the vaccine candidate. The team has “made incredible progress in developing a cocktail of antigens capable of producing antibodies using our ‘prime-boost’ method,” he said.

The funding comes during a busy year in HIV vaccine research and on the heels of an announcement by the NIH that it’s launching a large-scale Phase IIb/III HIV vaccine trial in South Africa later this year. That study will test HVTN 100--made up of one experimental vaccine each supplied by Sanofi Pasteur and GlaxoSmithKline ($GSK)--in 5,400 HIV-uninfected men and women with 5 injections over one year.

Aside from the NIH, players large and small have committed to the effort over the past year; Aelix Therapeutics launched with $12.7 million in January and the European Commission before that committed €23 million to a public-private partnership of 22 institutions.

For their approach, Lu and colleagues joined an in-house DNA vaccine with a recombinant protein-based vaccine. They’re expecting to further revamp the shot, according to a statement, and will work with clinical supply manufacturer Waisman Biomanufacturing on the next steps.

- here’s the release

Related Articles:
NIH to launch large-scale HIV vaccine trial in South Africa
European Commission launches €23M HIV vaccine research initiative
New HIV vaccine player Aelix Therapeutics hits the scene with $12.7M Series A


Suggested Articles

Astellas and Seattle Genetics are out with Padcev-Keytruda combo data that may be good enough to snag an expedited regulatory review, analysts say.

Distributors had offered billions of dollars to wrap up opioid litigation, but that effort has suffered a major setback, WSJ reports.

While no shortages of drug supplies have been reported, governments are trying to get a handle on what they can do if they materialize.